KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Prepaid Assets (2017 - 2025)

Aquestive Therapeutics has reported Prepaid Assets over the past 9 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $4.2 million for Q4 2025, up 26.84% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (up 26.84% YoY), and the annual figure for FY2025 was $4.2 million, up 26.84%.
  • Prepaid Assets for Q4 2025 was $4.2 million at Aquestive Therapeutics, up from $2.9 million in the prior quarter.
  • Over the last five years, Prepaid Assets for AQST hit a ceiling of $4.2 million in Q4 2025 and a floor of $1.2 million in Q2 2024.
  • Median Prepaid Assets over the past 5 years was $2.1 million (2022), compared with a mean of $2.4 million.
  • Biggest five-year swings in Prepaid Assets: plummeted 31.05% in 2023 and later soared 77.24% in 2024.
  • Aquestive Therapeutics' Prepaid Assets stood at $3.1 million in 2021, then tumbled by 30.74% to $2.1 million in 2022, then decreased by 13.0% to $1.9 million in 2023, then soared by 77.24% to $3.3 million in 2024, then grew by 26.84% to $4.2 million in 2025.
  • The last three reported values for Prepaid Assets were $4.2 million (Q4 2025), $2.9 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.